The potential of Artemisia species for use as broad-spectrum agents in the management of metabolic syndrome: a review
| Autor: | Kehinde Ahmad Adeshina, Dawoud Usman, Kennedy H. Erlwanger, Nyasha Charity Mukonowenzou, Kasimu Ghandi Ibrahim |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Cardiometabolic risk
biology Traditional medicine Physiology food and beverages Type 2 Diabetes Mellitus 030209 endocrinology & metabolism General Medicine Health benefits biology.organism_classification medicine.disease Obesity 03 medical and health sciences Broad spectrum 0302 clinical medicine 030220 oncology & carcinogenesis Physiology (medical) Diabetes mellitus medicine Artemisia Metabolic syndrome |
| Zdroj: | Archives of Physiology and Biochemistry. 129:752-770 |
| ISSN: | 1744-4160 1381-3455 |
| DOI: | 10.1080/13813455.2021.1871761 |
| Popis: | Although the prevalence of metabolic syndrome (MetS), a cluster of cardiometabolic risk factors that predispose to the development of type 2 diabetes mellitus and cardiovascular diseases, is increasing globally, there is no broad-spectrum agent for its holistic treatment. Natural plant-derived products with a wide spectrum of biological activities are currently being explored as alternatives in the management of diseases. Artemisia species are a heterozygous group of plants of the Compositae family that possess several health benefits. Here we highlight their antidiabetic, anti-obesity, anti-hyperlipidaemic, hepatoprotective and cardioprotective properties among others. These activities have been linked to the presence of phytochemicals that act on several molecular targets to exert their effects and the species of Artemisia are considered to be relatively safe. Artemisia species offer significant anti-MetS activity and thus are strong therapeutic candidates for the effective management of MetS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|